<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507479</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-13-0874-AN-CTIL</org_study_id>
    <nct_id>NCT02507479</nct_id>
  </id_info>
  <brief_title>Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies</brief_title>
  <official_title>Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypotheses is that the introduction of dose escalated thiotepa, in substitution to
      busulfan or melphalan, will reduce toxicity after allogeneic transplantation while improving
      disease eradication in patients with lymphoid malignancies not eligible for standard
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>The percentage of patients alive without disease recurrence 2 years after transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>The percentage of patients who die of complications related to the transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>graft versus host disease</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>The percentage of patients experiencing graft-versus-host disease after transplant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>2 years after transplantation</time_frame>
    <description>The percentage of patients experiencing disease recurrence after transplant</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Non Hodgkin Lymphoma</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>thiotepa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thiotepa 5-10 mg/kg/d x 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Chemotherapy given prior to allogeneic stem cell transplantation</description>
    <arm_group_label>thiotepa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age less than physiologic 68 years.

          2. Patients with MM, NHL, HL and CLL with an indication for allogeneic transplantation as
             follows:

               1. MM; patients relapsing after autologous transplant or with high-risk cytogenetic
                  abnormalities

               2. Aggressive lymphoma and Hodgkin lymphoma; relapse after autologous transplants

               3. Follicular lymphoma; failure of at least one prior regimen

               4. CLL; failure of prior therapy which includes Fludarabine combinations or 17p-
                  cytogenetic abnormality

          3. Patients must have an HLA matched related or unrelated donor willing to donate either
             peripheral blood stem cells or bone marrow. Matching is based on high-resolution class
             I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB) typing. The goal is to transplant &gt; 3
             x 106 CD34+ cells per kg body weight of the recipient

          4. Patients must sign written informed consent.

          5. Adequate birth control in fertile patients.

        Exclusion Criteria:

          1. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit

          2. Creatinine &gt; 2.0 mg/dl

          3. ECOG-Performance status &gt; 2

          4. Uncontrolled infection

          5. Pregnancy or lactation

          6. Abnormal lung diffusion capacity (DLCO &lt; 40% predicted)

          7. Severe cardiovascular disease

          8. CNS disease involvement

          9. Pleural effusion or ascites &gt; 1 liter

         10. Known hypersensitivity to Fludarabine or treosulfan

         11. Psychiatric conditions/disease that impair the ability to give informed consent or to
             adequately co-operate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Avichai Shimoni, MD</last_name>
    <phone>972 3 530 5830</phone>
    <email>ashimoni@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnon Nagler, MD</last_name>
    <phone>9972 3 530 5830</phone>
    <email>a.nagler@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnon Nagler, MD</last_name>
      <phone>972 3 530 5830</phone>
      <email>a.nagler@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Avichai Shimoni, MD</last_name>
      <phone>972 3 530 5303</phone>
      <email>ashimoni@sheba.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Avichai Shimoni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnon Nagler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2015</study_first_submitted>
  <study_first_submitted_qc>July 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

